Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Sep - Newspaper Publication - Corrigendum to 86th AGM Notice- Cut-off date & Book Closure period FY 2025-26.
Source: Bse
FDC Limited (FDC)
Small CapPharma stocks · Small cap · NSE
FDC Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result05 Aug, 08:34 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
65BullishMACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 42
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
FDCD candles · FIT view-6.2%Latest close ₹343.45 on 2026-10-19
Bar
-2.2%
RSI
49
MACD hist
2.29
52W pos
19%
2026-10-19O ₹351.20H ₹353.20L ₹340.35C ₹343.45Vol 1.9L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
FDCNifty PharmaNifty 500
- FDC
- -17.8%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -12.2 pp
Chart stats
19 Oct 2026- From 52W high
- -27.5%
- 52W range position
- 19%
- ATR (14)
- 3.4%
- Volume vs 20D
- 1.60x
- Avg traded value
- ₹4.2 Cr
- 20D price channel
- ₹321.3 - ₹365.6
₹473.6
₹313 - ₹473.6
₹11.8
Latest completed session
20-session average
32.2% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST40
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad27
Revenue +3.1% · PAT +9.1% YoY
Technical
Bullish65
Price trend and sector-relative-strength timing.
Valuation
Legacy model-180.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence75
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 27/100margin compression · Rev +3% YoY · PAT +9% YoY · +14% QoQ · operating leverage
Filed 05 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹668 Cr | +3.1% | +14.2% |
| EBITDA | ₹143 Cr | +2.1% | +34.9% |
| Operating margin | 21.0% | -100 bps | +300 bps |
| PAT | ₹132 Cr | +9.1% | +28.2% |
| PAT margin | 19.8% | +109 bps | +215 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 17.50
- P/B
- 2.16
- EV/EBITDA
- 13.74
- Market Cap
- 5400.00Cr
Profitability
- ROE
- 11.20%
- ROCE
- 15.40%
- ROA
- 10.04%
- Dividend Y
- 1.51%
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- -1.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 12.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 67.00×
- Altman Z
- 8.62
- Book Value
- 153.00
Cash Flow
- FCF Yield
- 1.67%
- FCF Positive Y
- 11/5
- OCF
- 200.00 Cr
- EPS TTM
- 17.97
Shareholding
- Promoter Hold
- 69.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 11%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 668+14.2% vs prev
Net Profit
₹ CrLatest: 132+28.2% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 49. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 roughly flat — short-term momentum stalled.
- RSI(14) at 49 — sideways, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 27% off 52W high · 10% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
39
RS percentile
Stage 4 Downtrend
1M return
-2.6%
3M return
-17.8%
6M return
-4.3%
1Y return
-20.5%
RS 1D
-3
RS 20D
+5
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 7.3% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -0.7%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 77.93-2.59%
RS vs Nifty 50078
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation6/30
Growth5/25
Quality4/20
Balance Sheet14/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
40
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
40/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 14/15 to the score.
- Cash flow contributes 5/10 to the score.
Main drags
- Fair-value margin of safety is negative at -180.2%.
- Valuation is weaker at 6/30; verify the latest quarterly trend.
- Growth is weaker at 5/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
17.5
PB
2.2
EV/EBITDA
13.7
ROE
11.2%
ROCE
15.4%
FCF Yield
1.7%
Debt/Equity
0.0
MoS
-180.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
40
Previous: 40
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-180.2%
Previous: -180.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
43
42
42
42
39
39
40
40
39
39
40
40
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹248.72
-38.1% MoS
Growth-justified P/E
6.8
Growth-justified Value
₹122.56
-180.2% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 167
40
49.7
11.6%
-8%
WATCHLIST
INNOVACAP
Small
Innova Captab Limited
Pharmaceuticals
match 165
48
42.6
13.7%
+17%
FAIR VALUE
ZOTA
Small
Zota Health Care LImited
Pharmaceuticals
match 165
26
—
-15.0%
—
OVERVALUED
BLISSGVS
Small
Bliss GVS Pharma Limited
Pharmaceuticals
match 165
39
51.4
11.8%
-8%
WATCHLIST
GUFICBIO
Small
Gufic Biosciences Limited
Pharmaceuticals
match 165
28
57.3
10.1%
-23%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
FDC Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
75Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 78th percentile of the scored universe and 69th percentile within Pharma. Main check: results consistency is weak at 50/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
32 docs text-extracted · 14 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
78th percentile
overall median 67 · Pharma: 69th pctile, median 70 · Small: 80th pctile, median 66
Evidence depth
Financial-only
32 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
50
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 69.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.6%.
- ▸11 years of positive FCF.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
- ▸OPM spread across recent quarters is 15%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching FDC Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Newspaper Publication of the convening of the 86th Annual General Meeting of the Company.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 Aug - FDC reported Q1 FY27 revenue of Rs. 668 crore, PAT Rs. 132 crore, and received US FDA approval for Cefixime suspension.
Source: Bse
Announcement
Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015 4 Jun - Maharashtra FDA seized Enerzal stock at two depots and collected samples; company says operations continue normally.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 May - Information regarding the Notice of the opening of a special window for re-lodgment of the transfer requests of physical shares and for claiming of unclaimed …
Source: Bse
Announcement
Newspaper Publication - Corrigendum In Respect Of Postal Ballot Notice Dated 21St April, 2026 13 May
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
AnnouncementMar 2026
Mar 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 28 May - FDC reported Q4 FY26 PAT of Rs 103 crore and FY26 PAT of Rs 281 crore; also received U.S. FDA approval.
Source: Bse
AnnouncementMar 2026
Mar 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 May - FDC reported Q4 FY26 PAT up 167% to Rs103 crore; FY26 revenue rose 3%, with one USFDA approval.
Source: Bse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.